

## CERTIFICATE OF ANALYSIS

Product: **CANIVERM comprimate á 0,175 g**

Batch No.: **B013-03**

Expiry: **13.05.2022**

Date of production: **14.05.2020**

### Results of analysis:

| Tests                                  | Release limits                                | Shelf-life limits | Results           |
|----------------------------------------|-----------------------------------------------|-------------------|-------------------|
| Appearance                             | Light yellow tablets.                         |                   | conforms          |
| Content of original package            | 2 x 1 tbl., 6 x 1 tbl., 100 x 1 tbl.          |                   | conforms          |
| Microbiological quality                | It shall comply with Ph. Eur., Article 5.1.4. |                   | conforms          |
| Content of fenbendazole                | 35.625 – 39.375 mg/0.175 g                    |                   | 36.878 mg/0.175 g |
| Fenbendazole identity                  | Must comply.                                  |                   | conforms          |
| Content of pyrantel embonate           | 34.2 – 37.8 mg/0.175 g                        |                   | 35.03 mg/0.175 g  |
| Pyrantel identity                      | Must comply.                                  |                   | conforms          |
| Content of praziquantel                | 11.875 – 13.125 mg/0.175 g                    |                   | 12.361 mg/0.175 g |
| Praziquantel identity                  | Must comply.                                  |                   | conforms          |
| Weight uniformity of tablets           | 0.166 – 0.184 g                               |                   | 0.173 g           |
| Impurities of fenbendazole             |                                               |                   |                   |
| - content of oxfendazole               | max. 1.0 %                                    |                   | 0.0 %             |
| - any individual unidentified impurity | max. 1.0 %                                    |                   | 0.4 %             |
| - sum of impurities                    | max. 3.0 %                                    |                   | 0.8 %             |
| Impurities of pyrantel embonate        |                                               |                   |                   |
| - any individual unidentified impurity | max. 1.0 %                                    |                   | 0.3 %             |
| - sum of impurities                    | max. 3.0 %                                    |                   | 0.3 %             |
| Impurities of praziquantel             |                                               |                   |                   |
| - any individual unidentified impurity | max. 1.0 %                                    |                   | 0.0 %             |
| - sum of impurities                    | max. 3.0 %                                    |                   | 0.0 %             |
| Break down tablets                     | Must conform.                                 |                   | conforms          |

I certify that this product has been tested in the laboratories of Bioveta a.s. and has been found to meet specification requirements. Preparation is suitable with control regulations of the valid PN No. 317, spec.02.



*Handwritten signature*  
.....04/08/2020  
Mgr. Hana Nezvalová  
HEAD of QC, QP